ImmuCell Corporation (ICCC)
ImmuCell Corporation Debt to Equity Ratio: 0.1585
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ICCC Debt to Equity Ratio Rankings
| Overall | 63rd percentile | 1547 of 4259 |
| Sector | 43rd percentile | 271 of 476 in Healthcare |
| Industry | 25th percentile | 12 of 16 in Diagnostic Substances |
ICCC Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.00 | Jun 2007 |
| Maximum | 0.1674 | Mar 2011 |
| Average | 0.0457 |
About Debt to Equity Ratio
YCharts Calculation: Debt to Equity = (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity
The debt to equity ratio is a leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. It reveals how a company has financed its assets. A low debt to equity ratio indicates lower risk because shareholder's have claims on a larger portion of the company's assets.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
You may also be interested in these ICCC related companies
ICCC News
ImmuCell Announces Product Sales Growth and Other Financial Results for 2011
Feb 13, 8:01AM Benzinga
Feb 13, 8:01AM Benzinga
ImmuCell Presents Mast Out(R) Product Offering at World Animal Health Congress
Dec 08, 8:00AM Marketwire
Dec 08, 8:00AM Marketwire
ImmuCell Announces Product Sales Growth and Other Financial Results for Third Quarter of 2011
Nov 14, 8:00AM Marketwire
Nov 14, 8:00AM Marketwire
ImmuCell Announces Product Sales Growth and Other Financial Results for Second Quarter of 2011
Aug 15, 8:00AM Marketwire
Aug 15, 8:00AM Marketwire
=> $ICCC $6.97 Tomsche David Scott director P 1,873 @ $6.63 amnt $12,410 proc'd $641 7/12/2011
about 322 days ago by canarionyc
about 322 days ago by canarionyc
$ICCC is a thinster but worth keeping an eye on as it continues to hit new highs in a weak tape
about 342 days ago by sXc_Capital
about 342 days ago by sXc_Capital
NASDAQ 3 biggest advancers: $HOKU 38.32%, $ICCC 26.06%, $DSCO 22.52%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies
about 972 days ago by datajunkies
about 972 days ago by datajunkies
NASDAQ 3 biggest advancers: $HOKU 38.32%, $ICCC 26.06%, $DSCO 22.52%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies
about 972 days ago by datajunkies
about 972 days ago by datajunkies
NASDAQ 3 biggest advancers: $HOKU 38.32%, $ICCC 26.06%, $DSCO 22.52%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies
about 972 days ago by datajunkies
about 972 days ago by datajunkies
NASDAQ 3 biggest advancers: $HOKU 38.32%, $ICCC 26.06%, $DSCO 22.52%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies
about 972 days ago by datajunkies
about 972 days ago by datajunkies
NASDAQ 3 biggest advancers: $HOKU 85.22%, $ICCC 54.58%, $DSCO 34.23%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies
about 973 days ago by datajunkies
about 973 days ago by datajunkies
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ICCC | 5.950 | -0.00 | -0.00% | 17.97M |
| ICB | 17.62 | -0.10 | -0.54% | |
| ICAD | 0.51 | +0.03 | +6.01% | 25.95M |
| ICA | 6.22 | +0.19 | +3.15% | 930.37M |
| IBOC | 18.67 | +0.17 | +0.92% | 1.245B |
| IBN | 30.14 | +0.85 | +2.92% | 16.88B |
| IBM | 196.55 | +2.25 | +1.16% | 225.13B |
| GTY | 16.26 | +0.05 | +0.31% | 541.25M |
| GTXI | 3.14 | +0.07 | +2.28% | 192.80M |
| GTU | 57.54 | -0.86 | -1.47% |
